LENZ Therapeutics, Inc.
LENZ
NASDAQ·Healthcare·Biotechnology·Mkt cap $186.9M
$5.96
▲ +2.23%
P/E
-1.46
Mkt Cap
$186.9M
52-Wk Range
$4.54–$50.40
52-Week Range
$4.54 - $50.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 85.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual product candidates (LNZ100 and LNZ101) in advanced Phase III clinical trials
- Focused approach to large, underserved presbyopia market with limited treatment options
- Specialized expertise in vision improvement and ophthalmology therapeutics
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Revenue decline expected
Successful Phase III trial completion and potential FDA approval of LNZ100/LNZ101
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-11.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LENZ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 11, 2026
Reported EPS of -$1.02 vs -$1.05 consensus (+2.9% surprise). Revenue of $5.5M vs $2.4M expected (+130.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$5.0M
$12.5M
$1.6M
$1.9M
$5.5M
Margins · last 8Q
Gross
94.9%
Operating
—
Profit
-581.8%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 12, 2026
vs Industry
How LENZ stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related